Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 4.05T |
| Revenue (ttm) | 525.78B |
| Net Income (ttm) | 109.29B |
| Shares Out | 2.40B |
| EPS (ttm) | 45.60 |
| PE Ratio | 37.01 |
| Forward PE | 32.47 |
| Dividend | 16.00 (0.95%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 2,404,269 |
| Average Volume | 2,793,480 |
| Open | 1,666.80 |
| Previous Close | 1,687.40 |
| Day's Range | 1,661.10 - 1,700.00 |
| 52-Week Range | 1,460.90 - 1,960.35 |
| Beta | 0.38 |
| RSI | 46.16 |
| Earnings Date | May 22, 2025 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and othe... [Read more]
Financial Performance
In 2024, NSE:SUNPHARMA's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
Compliance review: Sun Pharma’s Halol plant gets 8 USFDA observations; company vows remedial steps after inspection
Sun Pharmaceutical Industries faces scrutiny. The USFDA issued a Form 483. This follows an inspection of its Halol manufacturing plant in Gujarat. The inspection occurred between June 2 and June 13, 2...
Sun Pharma’s Halol facility receives form 483 with 8 observations from US FDA
Sun Pharmaceutical Industries Limited, one of India’s leading pharmaceutical companies, has announced the conclusion of a recent inspection by the United States Food and Drug Administration (US FDA) a...
Sun Pharma elevates Kirti Ganorkar as MD; Dilip Shanghvi to stay on as exec chairman
Sun Pharma's India business head, Kirti Ganorkar, will become the managing director on September 1, succeeding founder Dilip Shanghvi. Shanghvi will transition to executive chairman, while his son Aal...
Nifty 50 top losers today, June 6: HDFC Life, Bharat Electronics, Bharti Airtel, Tata Steel and Sun Pharma
Indian equity markets ended on a strong note today following a surprise monetary easing by the Reserve Bank of India (RBI). The central bank reduced the repo rate by 50 basis points and cut the Cash R...
SPARC shares drop nearly 20% after key drug trial fails
Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044)...
Nifty 50 top gainers today, May 29: IndusInd Bank, Sun Pharmaceutical, Eternal, Adani Ports and Trent
Indian equity markets showcased strong momentum on May 29, with benchmark indices ending the day in the green. The BSE Sensex surged 320.70 points or 0.39%, closing at 81,633.02, while the Nifty 50 ad...
Macquarie sees buying opportunity in pharma, stays bearish on hospital stocks
Macquarie has turned selectively bullish on the healthcare sector following the recent correction in Indian pharma formulation stocks, driven in part by concerns over global tariff threats. The broker...
Nifty 50 top losers today, May 23: Sun Pharmaceutical, Grasim Industries and Bharti Airtel
The Indian equity markets demonstrated robust performance today, May 23, 2025, with key benchmark indices closing firmly in the green. The BSE Sensex surged by 769.09 points, a gain of 0.95%, closing ...
Sun Pharma shares drop over 4% as Q4 misses estimates
Sun Pharmaceutical Industries Ltd. saw its shares drop over 4% in morning trade on Friday after the company announced its Q4 results. As of 9:15 AM, the shares were trading 3.53% lower at Rs 1,658.00....
Stocks in news on May 23: NTPC Green, Tata Steel, Adani Ports, Deepak Fertilizers, Sun Pharma, Ramco Cement, ITC, and more
Mumbai, May 23, 2025 – A flurry of earnings announcements and corporate updates have placed several stocks in focus for today’s trading session. From robust profit growth in sectors like cement, sugar...
Stocks to watch today: BEL, Tata Power, Sun Pharma, Ramco Cement, and ITC in focus on brokerage actions
Multiple brokerage firms have released updated recommendations on key Indian stocks following Q4FY25 results and recent corporate developments. Here’s a roundup of what fund houses are saying: BSE sha...
HSBC cuts trims Sun Pharma target price to Rs 1,870 on cost spike from specialty launches
HSBC has maintained its ‘Buy’ rating on Sun Pharma but lowered its target price to ₹1,870, following a miss in Q4 earnings and the company’s announcement of $100 million in additional costs for new sp...
Goldman Sachs maintains ‘Sell’ call on Sun Pharma stock, warns on growth visibility and FX headwinds
Goldman Sachs has retained its ‘Sell’ rating on Sun Pharma, keeping the target price unchanged at ₹1,475, despite a solid Q4FY25 operational performance. The brokerage remains cautious on valuation an...
Nomura maintains ‘Neutral’ on Sun Pharma, flags margin risks as investments rise in FY26
Nomura has retained its ‘Neutral’ stance on Sun Pharma with a target price of ₹1,970, stating that Q4FY25 performance came in below expectations, primarily due to lower US revenue contribution. The br...
Citi maintains ‘Buy’ on Sun Pharma post Q4 with target price of Rs 2,220; bets on specialty push despite EPS cut
Citi has maintained its ‘Buy’ rating on Sun Pharmaceutical Industries with a target price of ₹2,220, noting that Q4FY25 results were largely in line with expectations. The brokerage remains optimistic...
Sun Pharma Q4FY25: Revenue up 8% YoY to Rs 12,959 crore, profit drops 19% to Rs 2,154 crore
Sun Pharmaceutical Industries reported a mixed set of earnings for the fourth quarter of FY25, with net profit declining 19% year-on-year to Rs 2,153.9 crore, down from Rs 2,658.7 crore in the same pe...
Q4 FY25 results today: ITC, Sun Pharma, Grasim, Emcure, ConCor, Honasa, Deepak Fertilisers, among 50+ companies to declare earnings
A busy day lies ahead for investors on Wednesday, May 22, as more than 50 companies across sectors are scheduled to announce their financial results for the quarter ended March 31, 2025 (Q4 FY25). The...
Stocks to watch on May 22: IndiGo, Nalco, Mankind Pharma, Colgate in focus after Q4 results; ITC, Sun Pharma, Grasim to report today
A host of major Indian companies are in focus today, May 22, as investors react to fresh earnings reports and await key results. Companies across diverse sectors—from aviation and infrastructure to ph...
Stocks to watch on news today: Dr Reddy’s, Sun Pharma, BEL, JSW Steel, NBCC, Max Healthcare, PNC Infra in focus
Several companies are likely to remain in focus today owing to key regulatory updates, project wins, acquisitions, and strategic corporate announcements. Dr Reddy’s Laboratories received two observati...
Stocks to watch today on May 19: Hyundai, Waaree, IRCTC, IndusInd, Sun Pharma, NBCC, BEL in focus
A host of developments across corporate earnings, regulatory updates, and strategic announcements are likely to influence stock market activity today, May 19. Hyundai Motor India has recommended a fin...
Nifty 50 top losers this week (May 17): IndusInd Bank, Bharti Airtel and Sun Pharmaceutical
India’s benchmark stock indices—Nifty 50 and Sensex—posted a strong weekly performance, climbing sharply as investor sentiment improved. Both indices surged over 4%, marking one of the best weekly gai...
Nifty 50 top gainers today, May 13: Bharat Electronics, Jio Financial Services, Hero MotoCorp, Sun Pharmaceutical and more
The Indian stock market witnessed a sharp decline, with benchmark indices closing significantly lower. The Nifty 50 settled at 24,578.35, down 346.35 points or 1.39%, while the Sensex plunged 1,281.68...
Citi, Nomura cautious on pharma after US price control move; Sun Pharma seen at risk
Global brokerages Citi and Nomura have flagged potential risks for Indian pharmaceutical companies following the proposed US executive order aimed at slashing drug prices by 30–80%. Both brokerages se...
Sun Pharma drops 5.45%, Lupin down 2.44% as pharma shares react to Trump’s drug price order
Pharmaceutical stocks came under pressure on Monday morning despite a broader market rally, following remarks by former U.S. President Donald Trump. At 9:24 AM, the Sensex was up 1,855.97 points at 81...
Nifty 50 top losers this week (May 10): Sun Pharmaceutical, Asian Paints, IndusInd Bank, Jio Financial Services and more
The Indian share markets wrapped up the week on a bearish note, with benchmark indices registering notable declines amid global uncertainty and domestic profit-booking. The BSE Sensex fell by 880.34 p...